Conclusion:
Effectiveness of therapy can be better determined by PET-imaging measurements of genomic biomarkers targeted specifically, than by PET imaging of metabolic activity of a tumor. Cu-64-PNA PET-imaging provides a genetic tool for evaluation of therapeutic efficacy. Support: NIH 1R44CA136306. IP Licensed from E. Wickstrom/M. L. Thakur.
Materials and Method:
Peptide Nucleic Acid (PNA) that would hybridize with HER2 mRNA was synthesized together with D (CSKC), a cyclic peptide, that facilitated internalization of the PNA via IGFR expressed on breast (BC) cancer cells and DOTA that chelated Cu-64. Mice (n=8) with BT474 ER+/HER2+ human BC received doxorubicin (DOX), 1.5 mg/kg) intraperitoneally, three times a week. Mice (n=3) without DOX treatment served as controls. All mice were PET imaged with F-18-FDG and 24-48 hrs later with Cu-64-PNA. PET imaging was performed before and 72 hrs after each treatment. Standard Uptake Values (SUV) for tumors were determined and % change calculated. Animal body weight (BW) and tumor volume (TV) were measured.
Results: Following each of the three DOX treatments, tumor SUV for Cu-64-PNA declined to 54±17%, 41±15%, 29±7% of pretreatment SUV (P<0.05), as compared to 42±22%,31±18%, 13±9% (P<0.05), SUVs respectively for F-18-FDG. In control mice the corresponding % SUVs for Cu-64-PNA were 145±82% , 165 ±39 and 212±105%, and for F-18-FDG 108±28%, 151±8 and 152±35%. In treated mice, at the end of three DOX treatments, BW was 101.7±12.7% while TV declined to 35.1±35%. In control mice, BW remained 107.8±9.3% and TV averaged 181.3±51.5%. 
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